Aging seniors to reap long-term health benefits from Edmonton-based artificial intelligence project
Aging seniors to reap long-term health benefits from Edmonton-based artificial intelligence project
Search
Home Health Monitoring
Read more about the HHM Project that provides a community-based home health monitoring digital solution for people living with chronic conditions.
Boehringer Ingelheim (Canada) Ltd. and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials
Boehringer Ingelheim (Canada) Ltd. and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials
Vancouver General Hospital pilots new plant-rich menu items for health of patients and planet
Vancouver General Hospital pilots new plant-rich menu items for health of patients and planet
University Health Network and Boehringer Ingelheim Canada partner to impact patients lives and help a healthcare system under strain
University Health Network and Boehringer Ingelheim Canada partner to impact patients lives and help a healthcare system under strain
New collaboration between Boehringer Ingelheim and Sleip leverages AI technology to help detect lameness in horses
New collaboration between Boehringer Ingelheim and Sleip leverages AI technology to help detect lameness in horses
Ensho Health
Boehringer Ingelheim Canada, community cardiologists, and Ensho Health collaborated to create a tool optimizing care for chronic conditions in Alberta. More info.
Vancouver Coastal Health
VCH collaborates with Boehringer Ingelheim Canada's team to expedite healthcare solutions, enhance health outcomes, and drive sustainable change. Read more.
Aservo™ EquiHaler™, industry-first therapy for severe equine asthma, now available in Canada
Aservo™ EquiHaler™, industry-first therapy for severe equine asthma, now available in Canada
Indigenous Peoples living with diabetes is the focus of four new health pilot projects in Ontario, Nunavut, Alberta, and Manitoba
Indigenous Peoples living with diabetes is the focus of four new health pilot projects in Ontario, Nunavut, Alberta, and Manitoba
Breathing new life into patient care: Innovative partnership aims to transform interstitial lung disease support
Burlington, ON (October 25, 2023) – In a unique partnership, Boehringer Ingelheim (Canada) Ltd., St. Joseph's Healthcare Hamilton, and McMaster University have come together to transform the way patients are supported at the onset of a diagnosis
Boehringer Ingelheim receives Health Canada approval for SENVELGO™, the once-daily liquid oral solution for newly diagnosed diabetes in cats
Boehringer Ingelheim receives Health Canada approval for SENVELGO™, the once-daily liquid oral solution for newly diagnosed diabetes in cats
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
• Medicines reached a record 30 million people, driven by JARDIANCE® and OFEV® • R&D investments of 5 billion EUR, or 21 percent of net sales • Net sales rise 10.5 percent (currency adjusted), up strongly to 24.1 billion EUR
Boehringer Ingelheim (Canada) Ltd. partners with LMC Healthcare on national diabetes prevention program
Boehringer Ingelheim (Canada) Ltd. partners with LMC Healthcare on national diabetes prevention program
University of Guelph’s Dr. Charlotte Winder named 2023 Metacam® 20 Bovine Welfare Award winner
University of Guelph’s Dr. Charlotte Winder named 2023 Metacam® 20 Bovine Welfare Award winner
Alberta’s Dr. Karen Schwartzkopf-Genswein named 2022 Metacam® 20 Bovine Welfare Award winner
Award recognizes outstanding contributions to the welfare of animals in Canada
New collaboration to improve the detection of type 2 diabetes in high-risk patients starts in Montreal, Quebec
The project will use artificial intelligence (A.I.), wearable technologies and electronic health record systems to identify patients who may have type 2 diabetes in Montreal, Quebec
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales) More than 25 billion EUR investment in R&D and 7 billion EUR in capital expenditure over the next five years Human Pharma pipeline acceleration: up to 15 new product launches
Boehringer Ingelheim Animal Health introduces Ingelvac® MycoMAX in Canada — the first and only commercially available swine vaccine for Mycoplasma hyorhinis
Boehringer Ingelheim Animal Health introduces Ingelvac® MycoMAX in Canada — the first and only commercially available swine vaccine for Mycoplasma hyorhinis
Life forward - Boehringer Ingelheim unveils its evolved company brand
Ingelheim, Germany, 30/10/2023 | Boehringer Ingelheim, a leading research-driven biopharmaceutical company, on Monday presented a new corporate branding that is designed to inspire deeper connection with the company’s diverse customers, partners
Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention
Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention
Speak Up
The Speak Up portal provides a safe environment to report potential violations and is open to any person worldwide. We take any reports of potential violations seriously.
Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase
Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase
Collaboration key to meeting consumers’ expectations for better animal welfare
Collaboration key to meeting consumers’ expectations for better animal welfare
Digital Clinical Support Tool Aims to Individualize Guidelines-Based Diabetes Care
BURLINGTON, ON – October 11, 2023 – Boehringer Ingelheim (Canada) Ltd. and BI X, the digital lab of Boehringer Ingelheim, have collaborated to introduce a new digital clinical support tool for Canadian healthcare professionals managing the care